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Mechanisms of Toxicity/Carcinogenicity and
Superfund Decisions
by James M. LaVelle*
Heavy metals that contaminate soils and water usually exist in various oxidation states and
form a number of compounds with different physical and chemical characteristics. These dif-
ferences are often reflected in dramatic variation in toxicokinetic and biologic properties. Such
variation in properties, critical in determining intrinsic toxicity, often causes a great deal of
uncertainty in analyses ofpublic health risks at sites where metal exposure is evaluated. In the
Superfund program, such uncertainties may substantially undermine attempts to characterize
potential impacts to populations exposed to metals from improperly disposed waste. In the case
of chromium, risk assessment uncertainties can be considerable and fall generally into two
categories. First, there is almost no information on potential health effects due to chronic oral
exposure to chromium-containing compounds, and a nonquantifiable and probably large uncer-
tainty exists in establishing no-effect levels. In fact, reference doses (RfDs) for CrII' and Crv' are
based on chronic studies in which no adverse effects were seen even at the highest dose.
Considerations of bioavailability, deduced from site characterization data, and acute toxicity
indicate that general application ofthese RfDs may lead to highly inaccurate estimations ofrisk.
Second, because of the ready reduction of Cr"' in biological systems, it has not been possible to
separate effects ofCr"' from those ofCrl. Thus, data on the relative toxicity and carcinogenicity
ofthese two species is sparse and difficult to interpret. Moreover, kinetic considerations make it
difficult to determine the site and rates ofreduction ofCr'. This makes prediction oftarget site
concentrations ofthe twospecies difficult. The problem is particularly acute following inhalation
exposure, since epidemiologic studies suggest that chromium induces lung cancer by this route,
yet animal studies show cancer induction at sites of injection in various tissues. Knowledge of
mechanisms of toxicity and carcinogenesis, along with a more complete empirical database,
would increase confidence in oral RfDs, assist in establishing inhalation RfDs, and help evaluate
the overall impact ofinhalation ofchromium on the induction of cancer.
Introduction
Risk assessment activities at hazardous waste sites
that have been placed on the National Priorities List
(Superfund sites) involve both assessment of current
and potential exposures related to contaminants at the
site and an evaluation of the relationship between ex-
posure to these contaminants and possible adverse
health effects. Confidence in the latter evaluation is often
dependent on the quality and quantity of experimental
evidence for toxic effects of a contaminant when speci-
fied doses are administered to laboratory animals. Low
confidence in these dose-response relationships implies
a great deal of uncertainty in quantitative estimates of
risk. Since uncertainties often are contentious in inter-
actions among the public, potentially responsible par-
ties, and EPA, efforts to reduce uncertainties in risk
assessments should be given high priority.
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In the case of chromium, dose-response relationships
are ielatively poorly defined, and this is the source of
considerable uncertainty in quantitation of risks due to
chromium exposure. Several problem areas, particularly
those involving carcinogenic mechanisms, were exten-
sively examined by other investigators during this
symposium and will not be considered in this discus-
sion. Instead, the focus ofthis presentation will be dose-
response relationships involving noncarcinogenic end
points. For such end points, EPA generally considers
the reference dose (RfD) to be the appropriate critical
toxicity value for purposes ofrisk assessment. The RfD
is intended to represent that amount of a substance
that can be consumed daily for a significant portion ofa
lifetime without inducing adverse health effects. For
chromium, RfDs have been established for "insoluble"
compounds where chromium is found in the +3 valence
state and for "soluble" compounds where chromium is
found in the +6 valence state. Generally, EPA consid-
ers a daily intake, estimated as part of an exposure
assessment, that exceeds the RfD as posing the poten-J. M. LAVELLE
tial for induction ofadverse effects in at least a portion
ofthe exposed population. Whether the RfD accurately
reflects the actual potential of a compound to produce
toxicity is dependent at least in part on how accurately
experimental studies measure the dose-response rela-
tionship.
Oral RfD for Insoluble Chromium(il)
Compounds
The RfD for insoluble Cr"' compounds, as described
in EPA's Integrated Risk Information Service (IRIS)
(1), is provided in Table 1. It is worthwhile to note that
the RfD is based on a single study in which there are
no toxic effects seen at any dose. The only way to derive
an RfD from this study is to assume that the highest
dose approximates a no-observable-adverse-effect level
(NOAEL) and to apply safety factors to arrive at an
RfD for humans. Recently, a site with the potential for
exposure to chromium in contaminated soil has provided
an opportunity to consider the soundness of this as-
sumption.
At the site in question, both Crl", primarily as en-
riched chromite ore, and Crvy, primarily as soluble chro-
mate salts, were present from uncontrolled releases from
a chromate production process. In particular, there is,
on-site, a large pile ofchromite ore which has been used
as a sandbox by neighborhood children in the past. Thus,
one exposure scenario used in evaluating risk on the
site involved the incidental ingestion of chromium in
the ore during trespassing events by children. Because
chromite is highly insoluble in water, it seemed reason-
able to use the RfD for insoluble Cr"' compounds in
quantifying risk. However, when the chromite ore was
sampled and analyzed for total chromium, the concen-
tration was found to be only 16 mg/kg. Since chromite
ore is a concentrate ready for use in dichromate pro-
duction, the expected concentration ofchromium would
be between 25 and 40% or 25,000 to 40,000 mg/kg. Thus,
the Contract Laboratory Procedures method, using a
digestion in hot concentrated nitric acid, apparently
solubilized only a small fraction of the total chromium
(U.S. EPA, unpublished report). If a similar small frac-
tion were solubilized in the digestive tract after inges-
tion, and 2% of the soluble Cr"' were absorbed (2), in-
gestion at the RfD rate would correspond to an absorbed
dose of Cr"' of a few nanograms per kilogram per day.
Even highly toxic metals such as lead are not measur-
ably toxic at such low doses. In fact, the average daily
absorbed dose oflead from dietary sources is estimated
to be about 325 ng/kg/day for a 6-year-old child (3).
Faced with these data, one must ask ifthe current RfD
for insoluble Crl" compounds is appropriate for chro-
mite ore and perhaps other insoluble Crl" forms.
Clearly, additional chronic studies are needed to ad-
equately define the chronic oral toxicity, if any, of the
commonly encountered Cr"' compounds.
Oral RfD for Soluble Chromium(VI)
Compounds
The IRIS entry for soluble Crvy compounds is pro-
vided in Table 2. As with Crl", the RfD is based on a
study in which no adverse effects were seen, even at
the highest administered dose. In this study, Crvi was
added to drinking water in concentrations up to 25 ppm.
It is interesting to note that this is five times the con-
centration of CrVI in water that produced nausea in a
single volunteer. This volunteer used chromate-con-
taining water in place of normal drinking water for a
single day (4). This is by no means a definitive study,
but it does suggest the possibility that toxicity follow-
ing ingestion of chromate may occur only at levels of
exposure that cause some acute symptoms. Again,
Table 1. Oral RfD summary for soluble Crv' compounds (6).
Study Critical Experimental Uncertainty Modifying
type effect doses!' factor factor RfD
Rat chronic No effects observed NOEL: 5% 20:ICr in diet 5 days/week for 100 10 1E+0 mg/kg/day
feeding study 600 feedings (1800 g/kg body weight average total dose) (as an insoluble salt)
LOAEL: none
aDose conversion factors and assumptions: 1800 g 20;1Cr/kg bodyweight x 1000 mg/g x 0.6849 Cr/g 203Cr/600 feeding days x 5 feeding days/
7 days =1468 mg/kg/day.
Table 2. Oral RfD summary for insoluble Cr"l' compounds (7).
Study Critical Experimental Uncertainty Modifying
type effect dosesa factor factor RfD
Rat 1-year, No effects reported NOAEL: 25 mg/L ofchromium as K2CrO4 500 1 5 x 10 W3mg/kg/day
drinkingstudy (converted to 2.4 mg ofCrv"/kg/day)
LOAEL: none
aDose conversion factors and assumptions: drinking water consumption = 0.097L/kg/day (reported).
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chronic toxicity studies are neededl in which doses are
sufficiently high to produce some adlverse effects. Such
stu(lies might need to addcress the potential problem of
nausea by using animals that are able to regurgitate.
Pharmacokinetics of Chromium(VI)
CrV' is clearly reduced to Cr"' in the body. In theory,
this reduction could profoundly affect the delivered dose
of chromium in either valence state to sites for toxic
action. For example, given IP, Cr"' causes extensive
damage to the kidney (2). Slightly higher (loses of Cr'"
cause a similar effect, but most of the chromium recov-
eredl in the urine is in the form ofCr"'. The inference is
that Cr'I is riapidly reduced in experimental animals and
that Cr"' is responsible for the toxicity seen. It follows
that, if substantial (lifferences exist in the ability of
humans and animals to reduce Cry', or if there is sub-
stantial individual variation in the ability of humans to
reduce Cr"i, there will be considlerable (lifficulty in ex-
trapolating animal results to humans or in interpreting
human epidemiological studies.
Some evidence that such differences may exist is prio-
videdl by Korallus (5). In his paper, clear differences in
dlistribution and excretion of chromium were foundl in
workers occupationally exposed via inhalation to Cr"1.
In fact, the data suggest two distinct populations, per-
haps genetically based, exist in the study populations
(Fig. 1). One group apparently reduced Cri' rapidly, an(d
large amounts of Cr"' were excrete(d in the urine. The
other group apparently reducedl Cry' more slowly andl
excreted less Cr"ll. Differences in reducing capacity wvere
thought to be based extracellularly in the blood. Appar-
ently, this finding has not yet been (luplicate(l in other
worker populations or by other investigators. Never-
theless, the study at least raises the question of how
differences in the ability to reduce Cr\' might influence
-
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toxicity. For example, one might imagine that rapidl
reduction of Cr"' in the bloocl would produce relatively
high concentrations of Cr"'. After filtration at the glo-
merulus, this Cr"' might concentrate in the urine, de-
livering a higher dose of the toxic chromium form to
the kidney tubules.
On the other hand, slow riecluction ofCry' in the bloocl
could allow the Cr"' to penetrate into cells. Once there,
reduction woulcl produce Cr"' intracellularly. Since Crl"'
crosses membranes very poorly (2), reduction would ef-
fectively trap the chromium inside of cells. Cells sus-
ceptible to the carcinogenic actions of chromium (or
other adverse effects) might thus receive a higher dose
in individluals that reduced Cr"' slowly in the blood. Such
indlividluals might be less susceptible to kidney dlamage
because oflower bloodl Cr"' levels. However, tissue Cr"'
levels might be higher, making slow reducers susceptible
to other toxic effects, includling cancer.
Finally, if the ability of blood to reduce chromate is
saturable in the riange of (loses that might be expected
in human exposures, there may be (lifferences in ex-
pecte(l toxicity when the dose absorbedl exceecls the
reducing capacity ofthe blood. That is, doses that satu-
rate the reduction capacity of the bloodl wouldl be ex-
pecte(l to increase tissue chromium levels regarclless of
an indlivi(lual's reducing capacity. Thus, at high (loses,
the concentration of chromium at target sites may be
better predicted by administered or exposed dose.
In any event, it seems clear that studlies on the phar-
macokinetics of chromium need to be carried out. Such
studies should include both human exposures and the
use of experimental animals and shouldl focus on esti-
mating (lose deliveredl to specific target sites, such as
the kidlney. In addition, more information is needed to
define the variation in blood-reducing capacity in the
human population stu(lies.
Summary
In summary, available (lata on chromium make risk
assessments using EPA critical toxicity values (RfDs)
very uncertain. The basic problem lies in our current
inability to confidently predict the (lose of chromium
that actually r-eaches its site oftoxic action in the body.
Examination of the RfD for insoluble Cr"' compoun(l
suggests that the RfD could overestimate risks by at
least a few orlders of magnitude for some Cr"' com-
poun(ls. Similar consi(leration of the RfD for soluble
Cr"' compounds reveals the possibility that toxicity
might occur only at doses high enough to cause acute
symptoms, such as nausea. Finally, the pharmacokinet-
ics of Cr'' after absorption may be complex and vari-
able in the human population. This suggests that there
could be human subgroups with greater sensitivity to
some ofthe potential toxic effects ofchromium. It seems
clear that risk assessments based on exposure to chro-
mium compounds could be improved dramatically with
increased attention among researchers to the kinetics
ofchromium in mammalian systems.
1'29130 J. M. LAVELLE
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